Amgen (AMGN) Short-Term Debt issuances (2011 - 2017)
Amgen's quarterly Short-Term Debt issuances came in at $540.0 million in Q3 2017, up 16.88% quarter-over-quarter from $462.0 million in Q4 2011.
Amgen has reported Short-Term Debt issuances for 2 years, with the latest figure at $540.0 million in Q3 2017.
- For the quarter ending Q3 2017, Short-Term Debt issuances changed N/A year-over-year to $540.0 million; the trailing twelve-month figure through Sep 2018 stood at $540.0 million (down 46.11% YoY), and the FY2011 full-year result was $762.0 million, changed N/A from the prior year.
- Short-Term Debt issuances for Q3 2017 stood at $540.0 million, up from $462.0 million in the prior quarter.
- The five-year high for Short-Term Debt issuances was $540.0 million in Q3 2017, with the low at $540.0 million in Q3 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 1.78 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 12.44 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -499.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 1.06 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -127.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 321.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 540.00 Mn |
| Sep 30, 2017 | 540.00 Mn |
| Dec 31, 2011 | 462.00 Mn |
| Dec 31, 2011 | 462.00 Mn |